AI stock analysis · Medical Devices · Last analyzed Jul 8, 2026
Compass Score
3.0/5
Call
Hold
Price
$9.29
AI Target
$16.73 +80.1%
AI Analyst Summary
Alphatec Holdings is a high-conviction medical device turnaround story, with 13.6% revenue growth, a remarkably low PEG of 0.48, and unanimous analyst Buy ratings from all 11 covering analysts — reflecting strong confidence in the company's spine surgery technology platform and its near-term path to profitability. A forward P/E of just 16.1x implies the market has yet to fully price in the earnings inflection, creating a compelling risk/reward setup. The primary risk is execution: as a still loss-making company, any stumble in revenue growth or gross margin expansion could meaningfully delay profitability and pressure the stock.
Catalysts
Continued revenue growth acceleration in the spine surgery segment, with Q3/Q4 results expected to demonstrate whether the 13.6% YoY growth rate is sustainable or expanding.
Earnings inflection milestone: achieving GAAP or adjusted profitability for the first time would validate the forward P/E of 16.1x and likely trigger a re-rating toward the $16.73 consensus price target.
Potential new product launches or surgical technology platform expansions within the spine space that could expand the addressable market and drive incremental revenue growth.
Fundamentals
PeN/A (loss-making) · 2.0/5
No trailing P/E available as the company is currently loss-making. However, the forward P/E of 16.1x is quite reasonable for a high-growth medical device company, suggesting the path to profitability is visible and near-term.
Peg0.48 · 5.0/5
PEG of 0.48 is well below 1.0, signaling that the market is significantly underpricing ATEC's growth trajectory. This is a strong valuation signal for a company with 13.6% revenue growth and an improving earnings outlook.
Analyst RatingStrong Buy consensus (1.3) · 5.0/5
11 out of 11 analysts rate the stock a Buy with zero Hold or Sell ratings. A consensus of 1.3 on the inverted scale reflects extremely high conviction across the coverage universe, a rare and bullish signal.
Trailing EPS is not reported due to losses, but 13.6% revenue growth is solid for the medical device sector, and the company beat EPS estimates in all 4 of the last 4 quarters, signaling an accelerating path toward profitability. The forward P/E of 16.1x implies meaningful near-term earnings inflection.
A perfect 4-for-4 EPS beat rate over the most recent 4 quarters demonstrates strong and consistent execution against expectations. Scored 4 rather than 5 due to limited 4-quarter history versus the preferred 8-quarter window.
A flawless recent EPS beat record combined with unanimous analyst Buy ratings and a low PEG suggests disciplined operational execution and credible capital allocation. Management appears to be effectively guiding the company toward profitability while sustaining double-digit revenue growth.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.